肝硬化食管胃底静脉曲张的药物治疗

摘要/Abstract

中图分类号:

R657.34

胡明礼, 王绮夏, 马雄. 肝硬化食管胃底静脉曲张的药物治疗[J]. 外科理论与实践, 2021, 26(03): 203-207.

HU Mingli, WANG Qixia, MA Xiong. Drug therapy for esophageal and gastric fundus varices in liver cirrhosis[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 203-207.

参考文献32

[1]	Alqahtani SA, Jang S. Pathophysiology and management of variceal bleeding[J]. Drugs, 2021, 81(6):647-667. doi:10.1007/s40265-021-01493-2 URL
[2]	Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11):1680-1704. doi:10.1136/gutjnl-2015-309262pmid:25887380
[3]	de Franchis R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: report of the Baveno Ⅵ Consensus Workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3):743-752. doi:10.1016/j.jhep.2015.05.022pmid:26047908
[4]	徐小元, 丁惠国, 贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 实用肝脏病杂志, 2016, 19(5):641-656.
[5]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2):406-460. doi:10.1016/j.jhep.2018.03.024 URL
[6]	Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013, 62(11):1634-1641. doi:10.1136/gutjnl-2012-304038pmid:23250049
[7]	杨连粤, 白雪莉. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(12):1241-1247.
[8]	Zanetto A, Garcia-Tsao G. Management of acute variceal hemorrhage[J]. F1000Res, 2019, 8:F1000 Faculty Rev-966. doi:10.12688/f1000research.19590.2 URL
[9]	Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review[J]. Aliment Pharmacol Ther, 2011, 34(5):509-518. doi:10.1111/j.1365-2036.2011.04746.x URL
[10]	Tandon P, Abraldes JG, Keough A, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics[J]. Clin Gastroenterol Hepatol, 2015, 13(6):1189-1196.e2. doi:10.1016/j.cgh.2014.11.019 URL
[11]	Ready JB, Robertson AD, Goff JS, et al. Assessment of the risk of bleeding from esophageal varices by conti-nuous monitoring of portal pressure[J]. Gastroenterology, 1991, 100(5 Pt 1):1403-1410. pmid:2013385
[12]	D′Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review[J]. Hepatology, 1995, 22(1):332-354.
[13]	Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin for acute esophageal variceal hemorrhage[J]. Aliment Pharmacol Ther, 2003, 17(1):53-64.
[14]	Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension[J]. Aliment Pharmacol Ther, 2003, 18(4):375-386. doi:10.1046/j.1365-2036.2003.01657.x URL
[15]	Wells M, Chande N, Adams P, et al. Meta-analysis: vasoactive medications for the management of acute variceal bleeds[J]. Aliment Pharmacol Ther, 2012, 35(11):1267-1278. doi:10.1111/j.1365-2036.2012.05088.x URL
[16]	Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage[J]. Hepatology, 2014, 60(3):954-963. doi:10.1002/hep.27006 URL
[17]	Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: a new view of an old problem[J]. Clin Gastroenterol Hepatol, 2015, 13(12):2109-2117. doi:10.1016/j.cgh.2015.07.012 URL
[18]	Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis[J]. Hepatology, 2017, 66(4):1219-1231. doi:10.1002/hep.29267pmid:28543862
[19]	Turco L, Villanueva C, La Mura V, et al. A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis[J]. J Hepatol, 2017, 66(1 Supplement):S103-S104.
[20]	Sersté T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J]. Hepatology, 2010, 52(3):1017-1022. doi:10.1002/hep.23775 URL
[21]	Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J]. Gastroenterology, 2014, 146(7):1680-1690.e1. doi:10.1053/j.gastro.2014.03.005pmid:24631577
[22]	Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices[J]. Aliment Pharmacol Ther, 2010, 32(7):859-871. doi:10.1111/j.1365-2036.2010.04418.x URL
[23]	Puente A, Hernández-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an upda-ted systematic review[J]. Liver Int, 2014, 34(6):823-833. doi:10.1111/liv.12452 URL
[24]	Bunchorntavakul C, Reddy KR. Pharmacologic management of portal hypertension[J]. Clin Liver Dis, 2019, 23(4):713-736. doi:S1089-3261(19)30043-1pmid:31563219
[25]	Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J]. Gastroenterology, 2004, 126(3):749-755. doi:10.1053/j.gastro.2003.12.007 URL
[26]	Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analy-sis[J]. Clin Gastroenterol Hepatol, 2017, 15(10):1521-1530.e8. doi:10.1016/j.cgh.2017.04.039 URL
[27]	Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis[J]. Gastroenterology, 2016, 150(5):1160-1170.e3. doi:S0016-5085(16)00043-3pmid:26774179
[28]	Tranah TH, Edwards LA, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70(5):982-994. doi:10.1136/gutjnl-2020-320786 URL
[29]	Trebicka J, Bork P, Krag A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):167-180. doi:10.1038/s41575-020-00376-3pmid:33257833
[30]	Gupta N, Kumar A, Sharma P, et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial[J]. Liver Int, 2013, 33(8):1148-1157. doi:10.1111/liv.12172 URL
[31]	徐小元, 丁惠国, 李文刚, 等. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10):1847-1863.
[32]	Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28(3):450-455. doi:10.1111/jgh.12070 URL

肝硬化食管胃底静脉曲张的药物治疗

Drug therapy for esophageal and gastric fundus varices in liver cirrhosis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献32

相关文章15

编辑推荐

Metrics

本文评价

[1]	Chang Jessica, 陈旭晓, 陈拥军.脾脏在肝癌合并肝硬化中的临床价值[J]. 外科理论与实践, 2023, 28(04): 394-398.
[2]	安宝燕, 郭清, 冯明洋, 徐玉敏, 蔡伟, 谢青, 王晖.aMAP、APRI、FIB-4及肝硬度评估乙型肝炎肝硬化患者食管胃静脉曲张程度的价值探讨[J]. 诊断学理论与实践, 2023, 22(02): 141-146.
[3]	杨文康, 张俊, 王淑秋, 祥巴央宗, 杨翠萍.我国云南香格里拉地区104例肝硬化患者的病因及临床特征分析[J]. 诊断学理论与实践, 2022, 21(06): 730-734.
[4]	张梦茵, 陈平, 袁晓琴, 蔡波尔, 吴云林.内镜下组织黏合剂联合硬化剂注射治疗胃静脉曲张临床研究及随访[J]. 外科理论与实践, 2022, 27(05): 443-447.
[5]	吴巍赵宏伟.雄激素性脱发药物治疗及新药研究进展[J]. 组织工程与重建外科杂志, 2021, 17(5): 445-.
[6]	周香雪, 黄海威.肝豆状核变性影像学研究进展[J]. 内科理论与实践, 2021, 16(05): 308-314.
[7]	赵英妹, 聂红明, 张珏, 黄燕.肝硬化患者凝血五项的测定及其临床意义[J]. 诊断学理论与实践, 2021, 20(05): 480-483.
[8]	张斌, 吴志勇.门静脉高压症食管胃底静脉曲张出血的个体化治疗和手术方式选择[J]. 外科理论与实践, 2021, 26(03): 185-188.
[9]	孙隆慈, 张斌.门静脉海绵样变致食管胃底静脉曲张的手术治疗(附1例报告)[J]. 外科理论与实践, 2021, 26(03): 226-230.
[10]	陈炜, 卜俊峰.肝功能评估方式及在门静脉高压症围术期的应用[J]. 外科理论与实践, 2021, 26(03): 212-216.
[11]	杨涛, 阴继凯, 鲁建国.腹腔镜技术在门静脉高压症外科手术中的前景[J]. 外科理论与实践, 2021, 26(03): 217-220.
[12]	崔然, 叶伦河, 王旭菁, 王永坤, 张琪祺, 王恺京, 王明, 戴陈新, 杨鹿笛, 董春秀, 陈波.腹腔镜脾切除联合贲门周围血管离断术治疗肝硬化门静脉高压症的近期临床结果[J]. 外科理论与实践, 2021, 26(03): 221-225.
[13]	李涛, 陈皓.肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(03): 189-194.
[14]	罗蒙, 李泓杰, 郑磊.肝硬化门静脉高压症发病机制的研究现状[J]. 外科理论与实践, 2021, 26(03): 195-198.
[15]	曾宁, 方驰华.数字智能化诊疗技术在门静脉高压症中的应用[J]. 外科理论与实践, 2021, 26(03): 199-202.